publication . Article . 2016

NEW ANTIPLATELET DRUGS. PART 2

Array B. Sumarokov;
Open Access English
  • Published: 01 Jan 2016 Journal: Racionalʹnaâ Farmakoterapiâ v Kardiologii, volume 7, issue 5, pages 637-643 (issn: 1819-6446, eissn: 2225-3653, Copyright policy)
  • Publisher: Stolichnaya Izdatelskaya Kompaniya
Abstract
Antiplatelet agents are a necessary component of modern therapy of atherosclerosis. The difficulties of the antiplatelet treatment lie in balance between the necessary therapeutic effect and the risk of excessive action, leads to the bleeding. The ability to monitor antiplatelet pharmacodynamics is still very limited. Pharmacology of antiplatelet drug has been developing rapidly. New antiplatelet drugs are on their way to clinical application — prasugrel, ticagrelor , elinogrel, thromboxane receptor inhibitors, thrombin receptors inhibitors. Clinical pharmacology of these drugs is different. Practitioner should know their specifics to avoid the development of ia...
Persistent Identifiers
Subjects
Medical Subject Headings: circulatory and respiratory physiologycardiovascular diseases
free text keywords: disaggregants, prasugrel, ticagrelor, elinogrel inhibitors, thromboxane receptor inhibitors, thrombin receptor inhibitors, lcsh:Therapeutics. Pharmacology, lcsh:RM1-950, lcsh:Diseases of the circulatory (Cardiovascular) system, lcsh:RC666-701, Antiplatelet drug, medicine.medical_treatment, medicine, Pharmacology, medicine.drug, Thromboxane receptor, business.industry, business, Clinical pharmacology, law.invention, law, Therapeutic effect, Elinogrel, Pharmacodynamics
Any information missing or wrong?Report an Issue